RxDoctor Payments Data

Bijan Sorouri, MD

Internal Medicine · Newark, DENPI 1114016615

Payments from drug & device makers

$2,529in general payments, 2019–2025

Across 109 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$679
  • AstraZeneca$352
  • Lilly USA, LLC$336
  • AbbVie$305
  • Ascensia Diabetes Care US Inc.$238
  • Esperion Therapeutics, Inc.$125
  • plus $495 from 10 others

What the payments were for

  • Food & beverage$2,529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,529 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$252,140
Medicare patients
369
Services billed
3,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$63,936
JardianceEmpagliflozin25$43,034
JanuviaSitagliptin Phosphate32$39,351
TrulicityDulaglutide19$32,730
EliquisApixaban22$28,587
RybelsusSemaglutide14$22,853
FarxigaDapagliflozin Propanediol17$18,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,557
Atorvastatin Calcium421$5,907
Rosuvastatin Calcium181$3,299
Albuterol Sulfate HfaAlbuterol Sulfate86$3,124
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf42$2,897
Losartan Potassium265$2,855
Omeprazole176$2,517
Levothyroxine Sodium236$2,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$116$86,78951 claims
Boehringer IngelheimJardiance$32$43,03425 claims
MerckJanuvia$55$39,35132 claims
Lilly USA, LLCTrulicity$336$32,73019 claims
AstraZenecaFarxiga$352$18,92817 claims
GSKTrelegy Ellipta$679$17,55722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →